New appointment at Micromet
This article was originally published in Scrip
Micromet, a US biopharmaceutical company developing proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, has appointed Barclay Phillipssenior vice-president and chief financial officer. He has served as a member of the company's board of directors since December 2000. From 1999 to August 2008, Mr Phillips was a managing director of Vector Fund Management.